



## Prostate-Specific Membrane Antigen (PSMA)

Guest Editor:

**Prof. Kambiz Rahbar**  
Department of Nuclear  
Medicine/Deputy Director,  
University Hospital Muenster,  
Muenster, Germany

Deadline for manuscript  
submissions:  
**closed (10 December 2022)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue is about Prostate-Specific Membrane Antigen (PSMA), which has been the subject of a huge number of studies during the last 25 years. PSMA is a transmembrane protein, highly expressed by prostate epithelial cells and strongly upregulated in prostate cancer. PSMA expression levels are directly correlated to androgen independence, metastasis, and prostate cancer progression.

PSMA targeted imaging and therapy have significantly changed the management of patients with prostate cancer: Prospective studies could show the superiority of PSMA PET compared to conventional imaging modalities for the staging of prostate cancer. Moreover, within the last decades, different radiolabeled ligands have been used for therapy in Phase I and II studies with extremely promising response rates in end stage prostate cancer patients. Lately, one of those ligands has been under evaluation in a Phase III trial (VISION).

This special issue will highlight the importance of the radio targeted diagnostic and therapy in prostate cancer using PSMA ligands.

Prof. Kambiz Rahbar  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)